Celgene Korea received sales approval of multiple myeloma treatment 'Pomalyst'
On August 4, Celgene Korea, a global pharmaceutical company specializing in cancer areas received sales approval of multiple myeloma treatment 'Pomalyst (ingredient pomalidomide)' from the Ministry of Food and Drug Safety. 'Pomalyst' received sales approval with the indication dexamethasone combi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
